RxDoctor Payments Data

Sarah Smith

Medical · Philadelphia, PANPI 1912026832

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $47,175 of the $65,079 with a category attached, or 72.5%. 15 manufacturers reported payments, led by Gilead at 35.5% of the total. Among medical clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$65,079in general payments, 2019–2025

Across 235 payments — averaging $276.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$23K
  • Viiv Healthcare Company$19K
  • Janssen Products, LP$14K
  • Merck$8K
  • Johnson & Johnson$457
  • AbbVie$380
  • plus $328 from 9 others

What the payments were for

  • Consulting fees$6,84011%
  • Speaking & faculty fees$47,17572%
  • Travel & lodging$6,65910%
  • Food & beverage$4,1456%
  • Education$2600%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,079 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala94$370,546
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf51$251,709
TivicayDolutegravir Sodium40$88,432
DovatoDolutegravir Sodium/Lamivudine29$84,736
GenvoyaElviteg/Cob/Emtri/Tenof Alafen16$59,949
TriumeqAbacavir/Dolutegravir/Lamivudi13$47,935
XifaxanRifaximin13$41,791
JulucaDolutegravir/Rilpivirine11$38,018
DelstrigoDoravirine/Lamivu/Tenofov Diso14$36,532
EdurantRilpivirine Hcl13$18,521
JardianceEmpagliflozin20$15,344
JanuviaSitagliptin Phosphate15$8,443
Synjardy XrEmpagliflozin/Metformin Hcl14$8,414
Abacavir-LamivudineAbacavir Sulfate/Lamivudine11$8,021
FarxigaDapagliflozin Propanediol11$6,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$23,126$430,495110 claims
Viiv Healthcare CompanyTivicay, Dovato, Triumeq, Juluca$18,822$259,12093 claims
Janssen Products, LPSymtuza$13,976$251,70951 claims
MerckDelstrigo, Januvia$7,989$44,97529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →